Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

NCT05053152 is registered in ClinicalTrials.gov with NRG Oncology as lead sponsor.

NCT NCT05053152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05053152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Double-Blinded, Placebo-Controlled Trial of PROstate OligoMETastatic RadiotHErapy With or Without ANdrogen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)
Lead sponsor
NRG Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
April 20, 2022
Completion date
February 1, 2034
Enrollment
194 (estimated)
Sites
245

Conditions

As the registry lists them; a condition with its own page is linked.

oligometastatic prostate carcinoma, prostate adenocarcinoma, prostate ductal adenocarcinoma, prostate intraductal carcinoma, stage ivb prostate cancer ajcc v8